PP225 Real-world data of ramucirumab plus docetaxel compared with docetaxel after immune-checkpoint inhibitors in stage IV non-small cell lung cancer patients
نویسندگان
چکیده
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Ramucirumab plus docetaxel became one the available options for subsequent treatment in NSCLC after REVEL study. In addition, immune-checkpoint inhibitors (ICIs) standard NSCLC. Combining ICIs with anti-vascular endothelial growth factor blockade many tries to overcome resistance. We present our real-world data ramucirumab compared stage IV patients. retrospectively collected clinicopathologic patients who were treated or second fourth line from 1st January 2019 31th October 2021 Samsung Medical Center. After EGFR, ALK ROS1 mutations excluded, 38 ramucirumab/docetaxel group and 183 included analysis. Primary endpoint was progression-free survival (PFS), secondary endpoints overall (OS) response rate (ORR). Variables age, significantly different between two groups. Ramucirumab/docetaxel showed better PFS than alone (p = 0.012) this Hazard ratio 0.59 (95% confidence interval 0.37 – 0.96). Median 6 months ramucirumab/ group, 2 group. multivariable analysis cox proportional hazard regression, only histology significant differences. Ramucirumab/ had 0.019). 14 (36.8%) 47 (25.7%) each achieved partial response. Only patient complete among all 18 (47.4%) 68 (37.2%) stable disease as best However, there no benefit regarding OS 0.45) even tends prolong ramucirumab/docetaxel. higher data. ORR also not groups
منابع مشابه
Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study
Aims: The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. We intended to compare the effectiveness of two commonly used regimens in real world practice. Methods: This single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage IIIB, IV) non-small cell lung cancer and Eastern Cooperative O...
متن کاملComparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study
Aims: The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. We intended to compare the effectiveness of two commonly used regimens in real world practice. Methods: This single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage IIIB, IV) non-small cell lung cancer and Eastern Cooperative O...
متن کاملCarboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.
AIM Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Chemotherapy-naïve patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m(2)) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m(2...
متن کاملMulticenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.
PURPOSE To evaluate the safety and efficacy of docetaxel and carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS In this multicenter, phase II trial, 33 patients with previously untreated stage IIIB (n = 8) or IV (n = 25) NSCLC received intravenous infusions of docetaxel 80 mg/m2 followed immediately by carboplatin dosed to AUC...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ESMO open
سال: 2022
ISSN: ['2059-7029']
DOI: https://doi.org/10.1016/j.esmoop.2022.100720